Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 27, 2026

Why Rare Earth Magnets Are the Real Battlefield Between the U.S. and China

View original at finance.yahoo.com
Why Rare Earth Magnets Are the Real Battlefield Between the U.S. and China OilPrice.com Market Commentary NEW YORK, Feb. 27, 2026 /PRNewswire/ -- The struggle for geopolitical supremacy is rapidly becoming a struggle over one critical resource - rare earth magnets…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rare-earth metallization and alloying is the least developed and most difficult capability to rebuild outside China, and is an experience-driven bottleneck that cannot be recreated quickly

    80% confidence
  • The struggle for geopolitical supremacy is rapidly becoming a struggle over rare earth magnets, which will determine whether the United States can build military equipment at scale

    80% confidence
  • No other North American supplier currently produces the same class of qualified heavy rare earth metals and alloys, and it is unlikely they will have capabilities to do so at scale for at least another 3 years

    80% confidence
  • Almost no one outside China can reliably turn rare earth oxides into finished metal on an industrial scale

    80% confidence
  • Rare-earth metallization is learned over long operating histories, not built on a schedule, and reaching stable magnet-grade output can take many years and in some cases decades

    80% confidence
  • Dysprosium and terbium are non-negotiable inputs for precision-guided missiles and missile-defense interceptors

    80% confidence
  • REalloys operates North America's only facility that has converted heavy rare earths into high-performance metals and alloys required for defense systems

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com